What is Memphasys?
Memphasys Limited is an Australian-based innovator specializing in the development and commercialization of advanced reproductive biotechnology. Its flagship offering, the Felix System, represents a significant breakthrough in sperm separation technology, utilizing patented methods to isolate highly viable sperm cells for clinical use. With CE Mark certification, the Felix device has established a footprint in IVF clinics across Europe, Australia, the Middle East, Japan, and New Zealand. The company operates at the intersection of medical device engineering and reproductive science, maintaining a focus on high-precision solutions that improve outcomes for patients undergoing fertility treatments. Through strategic collaborations with academic and clinical researchers, Memphasys continues to refine its product pipeline, aiming to set new standards in the efficacy and reliability of ART procedures globally.
How much funding has Memphasys raised?
Memphasys has raised a total of $3M across 1 funding round:
Other Financing Round
$3M
Other Financing Round (2021): $3M with participation from Andrew Goodall and Peter Investments
Key Investors in Memphasys
Andrew Goodall
An individual investor with a focus on supporting high-growth biotechnology and medical device enterprises.
Peter Investments
A private investment entity specializing in strategic capital allocation for emerging healthcare and life sciences companies.
What's next for Memphasys?
With the recent capital injection, Memphasys is poised to enter a new phase of enterprise-level scaling. The strategic roadmap likely involves expanding the distribution network for the Felix System into untapped markets while simultaneously investing in R&D to broaden its portfolio of fertility solutions. As the company transitions from a development-focused entity to a commercial powerhouse, the focus will shift toward operational excellence and regulatory navigation in key jurisdictions. Investors and stakeholders will be monitoring the firm's ability to convert this financial momentum into sustained market share growth, particularly as the demand for sophisticated, evidence-based fertility technologies continues to rise in the post-pandemic healthcare landscape.
See full Memphasys company page
